Orthotopic liver transplantation (OLT) can be a definitive treatment for patients with hepatocellular carcinoma (HCC). Prolonged waiting times for cadaveric livers, however, may lead to dropout from the waiting list or worsened post-OLT prognosis as a result of interval tumor progression. Percutaneo
Radiofrequency ablation for hepatocellular carcinoma and metastatic liver tumors: A comparative study
โ Scribed by Danny H. F. Chow; Lorraine H. Y. Sinn; Kelvin K. Ng; Chi Ming Lam; Jimmy Yuen; Sheung Tat Fan; Ronnie T. P. Poon
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 117 KB
- Volume
- 94
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
In most patients with cirrhosis, successful percutaneous ablation or surgical resection of hepatocellular carcinoma (HCC) is followed by recurrence. Radiofrequency ablation (RFA) has proven effective for treating HCC nodules, but its repeatability in managing recurrences and the impact of this appro
## Abstract ## BACKGROUND The objectives of this study were to clarify risk factors for local tumor recurrence and to determine which patients with hepatocellular carcinoma (HCC) are most suitable for a single session, single application of percutaneous radiofrequency (RF) ablation. ## METHODS F
No adequate randomized trials have been reported for a comparison between hepatic resection (HR) versus radiofrequency ablation (RFA) for the treatment of patients with very early stage hepatocellular carcinoma (HCC), defined as an asymptomatic solitary HCC <2 cm. For compensated cirrhotic patients